Abstract
Introduction: International guidelines are ambivalent regarding the recommendations for the management of clinical stage 1 (CS1) seminoma. Patients and Methods: During 2008-2013, 1,050 patients with seminoma CS1 were prospectively registered with regard to assessing management modality (radiotherapy, carboplatin, surveillance). Associations with tumor size, rete testis invasion, age, year of diagnosis, type of institution, and geographic location were assessed. Results: Of the total number of patients, 49.3% received carboplatin 1 course, 8.5% carboplatin 2 courses, 35.9% surveillance, and 6.3% radiotherapy. In 2013, surveillance increased significantly to 57.9%. Treatment decisions were significantly associated with rete testis invasion and tumor size. Carboplatin was applied significantly more in office clinics than elsewhere. There is some regional variation regarding treatment preferences. Conclusions: The rising acceptance of surveillance mirrors international trends. The associations with prognostic factors demonstrate care givers to be compliant with contemporary guidelines. The association with the type of institution suggests non-oncological factors to be also relevant in decision making.
Journal Section:
Editor's choice
References
1.
Znaor A, Lortet-Tieulent J, Jemal A, Bray F: International variations and trends in testicular cancer incidence and mortality. Eur Urol 2014;65:1095-1106.
[PubMed]
2.
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP: EAU guidelines on testicular cancer: 2011 update. Eur Urol 2011;60:304-319.
[PubMed]
3.
Ruf CG, Isbarn H, Wagner W, Fisch M, Matthies C, Dieckmann KP: Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing. Urol Oncol 2014;32:33.e1-e6.
[PubMed]
4.
Sokoloff MH, Joyce GF, Wise M; Urologic Diseases in America Project: Testis cancer. J Urol 2007;177:2030-2041.
[PubMed]
5.
Heinzelbecker J, Katzmarzik M, Weiss C, Trojan L, Michel MS, Haecker A: Changes of stage, predictive factors and adjuvant treatment modalities in seminomatous testicular cancer from 1987 to 2007 and their impact on the status of metastasis, recurrence-free and overall survival: a single-center analysis. Urol Int 2011;87:282-287.
[PubMed]
6.
Fosså SD, Aass N, Kaalhus O: Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989;16:383-388.
[PubMed]
7.
Horwich A: Radiotherapy in stage I seminoma of the testis. J Clin Oncol 2004;22:585-588.
[PubMed]
8.
Classen J, Schmidberger H, Meisner C, Winkler C, Dunst J, Souchon R, Weissbach L, Budach V, Alberti W, Bamberg M; German Testicular Cancer Study Group (GTCSG): Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer 2004;90:2305-2311.
[PubMed]
9.
Siekiera J, Małkowski B, Jóźwicki W, Jasiński M, Wronczewski A, Pietrzak T, Chmielowska E, Petrus A, Kamecki K, Mikołajczak W, Kraśnicki K, Chłosta P, Drewa T: Can we rely on PET in the follow-up of advanced seminoma patients? Urol Int 2012;88:405-409.
[PubMed]
10.
Horwich A, Fossa SD, Huddart R, Dearnaley DP, Stenning S, Aresu M, Bliss JM, Hall E: Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer 2014;110:256-263.
[PubMed]
11.
Oliver RT, Hope-Stone HF, Blandy JP: Justification of the use of surveillance in the management of stage I germ cell tumours of the testis. Br J Urol 1983;55:760-763.
[PubMed]
12.
Peckham MJ, Hamilton CR, Horwich A, Hendry WF: Surveillance after orchiectomy for stage I seminoma of the testis. Br J Urol 1987;59:343-347.
[PubMed]
13.
Peckham MJ, Horwich A, Hendry WF: Advanced seminoma: treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br J Cancer 1985;52:7-13.
[PubMed]
14.
Oliver RT, Lore S, Ong J: Alternatives to radiotherapy in the management of seminoma. Br J Urol 1990;65:61-67.
[PubMed]
15.
Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP; MRC TE19 Collaborators and the EORTC 30982 Collaborators: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005;366:293-300.
[PubMed]
16.
Classen J, Souchon R, Hehr T, Bamberg M: Treatment of early stage testicular seminoma. J Cancer Res Clin Oncol 2001;127:475-481.
[PubMed]
17.
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB; National Comprehensive Cancer Network: Testicular cancer. J Natl Compr Canc Netw 2012;10:502-535.
[PubMed]
18.
Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C: Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 2013;24:878-888.
[PubMed]
19.
Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V: Testicular seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v140-v146.
[PubMed]
20.
Mottet N, Culine S, Iborra F, Avances C, Bastide C, Lesourd A, Michel F, Rigaud J: [Testicular tumors]. Prog Urol 2007;17:1035-1045.
[PubMed]
21.
Howard GC, Nairn M; Guideline Development Group: Management of adult testicular germ cell tumours: summary of updated SIGN guideline. BMJ 2011;342:d2005.
[PubMed]
22.
De Giorgi U, Nicolai N, Tana S, Tavolini IM, Palazzi S, Bracarda S, Tedeschi L, Palmieri G, Frassineti L, Da Pozzo L, Pastorino U, Emiliani E, Marangolo M, Pizzocaro G, Rosti G, Salvioni R: IGG practice guidelines on germ cell tumor in adult male patients. Tumori 2008;94:96-109.
[PubMed]
23.
Dieckmann KP: Seminom klinisches Stadium I: immer noch Fragen offen. Die NSR-Studie - eine bundesweite Studie zur Versorgungsforschung. Urologe A 2009;48:419-422.
[PubMed]
24.
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz-Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H: European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European germ cell cancer consensus group (EGCCCG): part I. Eur Urol 2008;53:478-496.
[PubMed]
25.
Schrader M, Weissbach L, Hartmann M, Krege S, Albers P, Miller K, Heidenreich A: Burden or relief: do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer? Eur Urol 2010;57:867-872.
[PubMed]
26.
Zengerling F, Hartmann M, Heidenreich A, Krege S, Albers P, Karl A, Weissbach L, Wagner W, Bedke J, Retz M, Schmelz HU, Kliesch S, Kuczyk M, Winter E, Pottek T, Dieckmann KP, Schrader AJ, Schrader M: German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice. Oncol Rep 2014;31:2477-2481.
[PubMed]
27.
Zengerling F, Müller J, Schrader AJ, Schrader M: [Clinical stage I seminoma. Is surveillance a new therapy standard?]. Urologe A 2013;52:1265-1269.
[PubMed]
28.
Vossen CY, Horwich A, Daugaard G, van Poppel H, Osanto S: Patterns of care in the management of seminoma stage I: results from a European survey. BJU Int 2012;110:524-531.
[PubMed]
29.
Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, Stierner UK, Ståhl O, Cavallin-Ståhl EK, Klepp OH, Dahl O, Cohn-Cedermark G: Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian testicular cancer study group. J Clin Oncol 2011;29:719-725.
[PubMed]
30.
Cafferty FH, Gabe R, Huddart RA, Rustin G, Williams MP, Stenning SP, Bara A, Bathia R, Freeman SC, Alder L, Joffe JK: UK management practices in stage I seminoma and the medical research council trial of imaging and schedule in seminoma testis managed with surveillance. Clin Oncol (R Coll Radiol) 2012;24:25-29.
[PubMed]
31.
Grimison P, Houghton B, Chatfield M, Toner GC, Davis ID, Martin J, Hovey E, Stockler MR: Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU Int 2013;112:E35-E43.
[PubMed]
32.
Bilici A, Ozturk T, Turkmen E, Odabas H, Cihan S, Selcukbiricik F, Erdogan B, Urakci Z, Kandemir N, Bayoglu IV, Demirci U, Duran AO, Sendur MA, Yavuzer D, Harputluoglu H, Kavgaci H, Gumus M: Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian society of medical oncology. World J Urol 2015;33:1613-1622.
[PubMed]
33.
Kohut RM Jr, Minnillo BJ, Kypriotakis G, Abouassaly R, Zhu H: Changes in adjuvant therapy utilization in stage I seminoma: are they enough to prevent overtreatment? Urology 2014;84:1319-1324.
[PubMed]
34.
Scriba PC, Berger J: Versorgungsforschung: die Förderinitiative der Bundesärztekammer. Dtsch Med Wochenschr 2007;132:1424-1426.
[PubMed]
35.
Hoffmann F, Glaeske G: [Health services research in oncology using claims data]. Med Klin (Munich) 2010;105:409-415.
[PubMed]
36.
Ernstmann N: [On the importance of health services research: an overview]. Urologe A 2011;50:673-677.
[PubMed]
37.
Vlayen J, Vrijens F, Devriese S, Beirens K, Van Eycken E, Stordeur S: Quality indicators for testicular cancer: a population-based study. Eur J Cancer 2011;48:1133-1140.
[PubMed]
38.
Bagnell S, Choo R, Klotz LH, Chaterjee S: Practice patterns of Canadian urologists in the management of stage I testicular seminoma. Can J Urol 2004;11:2194-2199.
[PubMed]
39.
Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von Der Maase H: Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448-4452.
[PubMed]
40.
Dieckmann KP, Brüggeboes B, Pichlmeier U, Küster J, Müllerleile U, Bartels H: Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 2000;55:102-106.
[PubMed]
41.
Gray PJ, Lin CC, Sineshaw H, Paly JJ, Jemal A, Efstathiou JA: Management trends in stage I testicular seminoma: impact of race, insurance status, and treatment facility. Cancer 2015;121:681-687.
[PubMed]
42.
Hoffman KE, Chen MH, Punglia RS, Beard CJ, D'Amico AV: Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol 2008;26:3937-3942.
[PubMed]
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.
